NetworkNewsBreaks Archive - Page 2064 of 2081

WednesdayNov 09, 2016 3:39 pm

America Votes Trump; Investors Pounce on Healthcare Stocks

President-elect Donald Trump has long voiced his opposition of ObamaCare and the broader healthcare system, and though his stance on regulating drug prices remains uncertain, drug companies are likely to enjoy lesser scrutiny than they would from a Clinton Administration. In today’s market, here are several healthcare stocks trading higher near market close: Cigna Corp. (NYSE: C) Humana, Inc. (NYSE: HUM) Aetna, Inc. (NYSE: AET) UnitedHealth Group, Inc. (NYSE: UNH) Actinium Pharmaceuticals, Inc. (NYSE: NTM) AmerisourceBergen Corp. (NYSE: ABC) Biogen, Inc. (NASDAQ: BIIB) About NetworkNewsBreaks NetworkNewsBreaks (NNB) provide a rapid summary of corporate news that caught the attention of NetworkNewsWire (NNW).…

WednesdayNov 09, 2016 12:19 pm

Will the Trump Train Boost the Construction Industry?

Defying the drop in global markets and futures following Donald Trump’s presidential win, U.S. markets are higher in morning trade. If Trump achieves his vision to bring jobs back to American soil, it could mean big business for companies operating in various aspects of the building and construction trades. In today’s market, here are several construction stocks trading higher: Argan, Inc. (NYSE: AGX) Dycom Industries, Inc. (NYSE: DY) Emcor Group, Inc. (NYSE: EME) Comfort Systems USA, Inc. (NYSE: FIX) Granite Construction, Inc. (NYSE: GVA) Myr Group, Inc. (NYSE: MYRG) NV5 Group, Inc. (NYSE: NVEE) About NetworkNewsBreaks NetworkNewsBreaks (NNB) provide a…

WednesdayNov 09, 2016 10:17 am

Bristol-Myers Squibb Company (BMY), Infinity Pharmaceuticals, Inc. (INFI) Team Up to Evaluate Combination in Solid Tumors Study; Shares Jump

Shares of Bristol-Myers Squibb (NYSE: BMY) and Infinity Pharmaceuticals (NASDAQ: INFI) are higher after the companies announced their clinical trial collaboration to evaluate Bristol-Myers Squibb’s Opdivo in combination with Infinity’s IPI-549 in patients with advanced solid tumors. The dose-escalation portion exploring IPI-549 as a monotherapy in Infinity’s phase 1 study is continuing, and the first dose-escalation cohort studying IPI-549 in combination with Opdivo, a PD-1 immune checkpoint inhibitor, is scheduled to begin this fall. To view the full press release, visit: http://nnw.fm/V4tfN About Infinity Pharmaceuticals, Inc. Infinity is an innovative biopharmaceutical company dedicated to advancing novel medicines for people with…

TuesdayNov 08, 2016 2:07 pm

NetworkNewsBreaks – Top 10 Mid-day Percentage Gainers on November 8, 2016

Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: GLLK 56.25% - News: Gets green light for exploration work permit in Ontario JMDA 30.77% - News: Partners with lifestyle brand Willie’s Reserve NXGH 24.23% - News: Issues shareholder update ICAD 13.68% - News: Names Richard Christopher as executive VP and CFO PERI 11.22% - News: Posts Q3 results, non-GAAP EPS of $0.12 vs. $0.10 last year CLBS 8.17% - News: Q3 revenues increase 58% to $9.3M LPCN 8.05% - News: Narrows Q3 loss…

TuesdayNov 08, 2016 2:05 pm

Zosano Pharma Corp. (ZSAN) Completes Enrollment in Pivotal Efficacy Trial for Acute Migraine Treatment Candidate; Shares Higher

Shares of Zosano Pharma (NASDAQ: ZSAN) are trending higher in mid-day trade following early news that the company has completed enrollment in its registration-enabling, pivotal efficacy trial (the Zotrip trial) of M207 for the treatment of acute migraine. “The completion of enrollment in the Zotrip study is a major milestone for the Company and bolsters our confidence in the previously announced availability of trial data in the first quarter of 2017,” Konstantinos Alataris, PhD, president and CEO of Zosano Pharma, stated in the news release. “The enrollment pace is also indicative of the urgent need for improved treatment options for…

TuesdayNov 08, 2016 1:39 pm

Great Basin Scientific, Inc. (GBSN) Finishes Trial for Stool Bacterial Pathogens Panel; Shares Lower

Great Basin Scientific (OTCQB: GBSN) this morning reported the completion of its clinical trial of Stool Bacterial Pathogens Panel, a technology designed to detect Salmonella species, Shigella species, Shiga Toxin-producing E. coli species (stx1 and stx 2, O157), and Camphylobacter species (C. jejuni and C. coli). From here Great Basin intends to pursue 510(k) clearance from the Food and Drug Administration (FDA) as well as CE marking. To view the full press release, visit: http://nnw.fm/t5AgC About Great Basin Scientific Great Basin Scientific is a molecular diagnostics company that commercializes breakthrough chip-based technologies. The Company is dedicated to the development of…

TuesdayNov 08, 2016 10:50 am

ChromaDex Corp. (CDXC) Shares Tick Higher on $5M Credit Facility

ChromaDex (NASDAQ: CDXC) is trading higher this morning after announcing its $5 million credit facility with Bridge Bank. ChromaDex innovates proprietary health, wellness and nutritional ingredients that create science-based solutions to dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products. The company says the credit facility provides the capital needed to expand its proprietary ingredient business. To view the full press release, visit: http://nnw.fm/9joXj About ChromaDex: ChromaDex leverages its complementary business units to discover, acquire, develop and commercialize patented and proprietary ingredient technologies that address the dietary supplement, food, beverage, skin care and pharmaceutical markets. In addition…

TuesdayNov 08, 2016 10:47 am

Orexigen Therapeutics, Inc. (OREX) Inks Deal with Valeant Pharmaceuticals to Commercialize Contrave Weight Loss Drug; Shares Soar

Shares of Orexigen Therapeutics (NASDAQ: OREX) jumped more than 27% in morning trade after the company announced that its wholly owned subsidiary, Orexigen Therapeutics Ireland Ltd., will work with Valeant Pharmaceuticals International, Inc. to commercialize Orexigen’s weight loss drug, Contrave®, in Australia and New Zealand. Per the agreement, Valeant will be responsible for obtaining regulatory approvals and for all commercialization activities; Orexigen will supply Contrave tablets to Valeant for an agreed transfer price and certain potential sales milestone payments. Orexigen said it expects Valeant to file for regulatory approvals in both countries in the first half of 2017. To view…

MondayNov 07, 2016 1:17 pm

Net Element, Inc. (NETE) Set to Feast on Multi-Trillion Dollar Mobile Payments Market

In the rapidly evolving payments industry, more consumers are making purchases online or via mobile apps, putting the global mobile payments market on pace to reach $3 trillion by 2021. Amid this growing trend, progressive payment companies are staying ahead of the game by developing secure, convenient and reliable processing services. “In this vast landscape, a company such as Net Element, Inc. (NASDAQ: NETE) easily stands out for its versatility and dedication to offering value-added transactional services and high-quality mobile payment options to the global market. The company has several subsidiaries offering various payment processing solutions, ranging from comprehensive payment…

MondayNov 07, 2016 1:15 pm

Technology-driven eXp World Holdings, Inc. (EXPI) is Poised for Success in Canada’s Hot Housing Market

Though real estate in Canada is expected to pull-back from its all-time high, analysts are calling for continued stability in an environment welcoming the use of technology to better serve and interact with consumers. “ … ‘the main message is that every regional market offers opportunities for savvy developers and investors—as long as they embrace technology and anticipate their future buyers’ needs’ … With the technological factor in mind, it is no surprise that companies such as eXp World Holdings, Inc. (OTCQB: EXPI) are set to capitalize on Canada’s real estate market. With potential tenants and buyers more informed than…

Financial news and publishing for public and private companies

Contact us: 512.354.7000

NetworkNewsBreaks